ABCL · AbCellera Biologics Inc.
Market Cap
$3.94B
Shares
306.61M
Volume · Oct 2
3.71M
Avg daily vol (3M)
6.75M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.74
Open$14.10
Day$13.66–14.30
52W close$2.78–14.82
Avg vol 30d5.0M
Short int33.9M · 11.1% float · 9.6d
Short vol51%
Last earningsNov 9, 2026
DataDec 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings release
Nov 9, 2026
Announced
· in 5 wks
Next earnings call
Nov 9, 2026
Scheduled
· in 5 wks
filed Aug 5, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$66.17M
Trailing 12 months
Net income (TTM)
−$164.66M
Trailing 12 months
Revenue growth YoY
-76.3%
Year over year
Operating margin
-340.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-3.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.4%
Year over year · more shares
Price change (1Y)
+133.4%
Trailing year
Short interest
11.1%
Latest settlement · 9.6 days to cover
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. AbCellera closed ABCL635 Phase 2 enrollment ahead of schedule and expects a top-line data readout very soon, while signing two new T-cell engager collaborations with Jazz ($84M upfront) and Vertex ($28M upfront) that add over $110M in cash; Q2 revenue fell to $4.1M, R&D expense rose to $46.0M, and net loss widened to $55.4M, though the company ended with over $675M in total available liquidity.
Bullish
- + Signed new TCE collaborations with Vertex ($28M) and Jazz ($84M) adding over $110M in upfront cash and up to $4B in potential deal value
- + ABCL635 Phase 2 enrollment and initial dosing completed ahead of schedule with top-line data expected very soon
- + Liquidity strengthened with over $565M in cash/marketable securities plus ~$110M in committed government funding for over $675M total available liquidity, sufficient to fund at least the next three years
- + SG&A expense declined to $13.9M from $22.0M year-over-year
Bearish
- − Net loss widened to $55.4M ($0.18/share) from $34.7M ($0.12/share) year-over-year
- − R&D expense increased to $46.0M from $39.2M year-over-year, contributing to wider loss
- − Company missed its previously communicated goal of moving another program into IND-enabling activities in H1 2026
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+130%
above
Price vs 50-day avg
+30%
above
RSI (14)
64
neutral
MACD trend
Positive
52-week position
91%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+19%
trailing
6-month return
+275%
trailing
YTD return
+302%
this year
Relative strength
+263%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +39 funds added
Insider flow
Accumulating
Net +$1.5M over 90 days · 0% sells
Short interest
Falling
11.07% of float · ▼ -2.4% MoM · 9.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
150 holders — mid 3-yr range
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+161%
Y/Y
EPS growth
+11%
Y/Y
Free cash flow
$-174.1M
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+130%
Bullish
Price vs 50-day avg
+30%
Bullish
RSI (14)
64
Neutral
MACD trend
Positive
Bullish
52-week position
91%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $11 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +39 funds added
Insider flow
Accumulating
Net +$1.5M over 90 days · 0% sells
Short interest
Falling
11.07% of float · ▼ -2.4% MoM · 9.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
150 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $14 · 91%
Range high $15
vs 200-day avg +130%
vs 50-day avg +30%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABCL
this stock
AbCellera Biologics Inc.
|
$3.94B | +301.8% | +160.6% | — | 11.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABCL | +8.2% | +18.8% | +275.4% | -5.8% | +301.8% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +8.4% | +19.2% | +263.2% | -6.8% | +288.9% |